TCGA-97-A4M1-01A-11R-A24X-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.280
- KRAS_SIGNALING_DN+0.270
- BILE_ACID_METABOLISM+0.230
- COAGULATION+0.180
- PANCREAS_BETA_CELLS+0.140
- NOTCH_SIGNALING+0.060
- XENOBIOTIC_METABOLISM+0.050
- FATTY_ACID_METABOLISM+0.030
- APICAL_JUNCTION-0.050
- KRAS_SIGNALING_UP-0.060
Top 10 suppressed
- E2F_TARGETS-0.680
- G2M_CHECKPOINT-0.680
- MYC_TARGETS_V1-0.670
- MYC_TARGETS_V2-0.610
- MTORC1_SIGNALING-0.580
- UNFOLDED_PROTEIN_RESPONSE-0.560
- PROTEIN_SECRETION-0.460
- PI3K_AKT_MTOR_SIGNALING-0.440
- OXIDATIVE_PHOSPHORYLATION-0.430
- GLYCOLYSIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.932 |
| 2 | BS_V7BJM89K | low-grade glioma | — | 0.920 |
| 3 | TCGA-55-A4DG-01A-11R-A24H-07 | — | cohortA1 | 0.913 |
| 4 | SJEPD030_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.913 |
| 5 | SJEPD001530_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.909 |
| 6 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.908 |
| 7 | SRR1516074 | — | — | 0.907 |
| 8 | BS_C80S5N37 | EPN | EPN Tumor | 0.906 |
| 9 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.906 |
| 10 | TCGA-CF-A47Y-01A-11R-A23W-07 | — | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |